Andri Dwi Wahyudi
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia.

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis: [Hepatotoxicity Pharmacogenomic of Anti Tuberculosis Drugs] Andri Dwi Wahyudi; Soedarsono Soedarsono
Jurnal Respirasi Vol. 1 No. 3 (2015): September 2015
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (260.573 KB) | DOI: 10.20473/jr.v1-I.3.2015.103-108

Abstract

Anti-TB drugs (ATD) associated with hepatotoxicity is a serious medical problem in the world, especially for patients with TB. The production and expenditures toxic drug metabolites depends on the activity of some enzymes, such as N-acetyl transferase 2 (NAT2), Cytochrome P450 oxidase (CYP2E1) and Glutathione S-transferase (GSTM1). Variations from the DNA sequence or polymorphism at this locus (NAT2, CYP2E1 and GSTM1) can modulate enzyme activity and can affect the risk of hepatotoxicity. Hepatotoxicity is generally unpredictable and occur in a small number of patients even when the drug was given according to the recommended dosage. Among the ATD, the metabolism of INH, which is one of the ATD forefront, has been studied extensively, and said acetylation by NAT2, oxidation by cytochrome P450 oxidase (CYP2E1) and detoxified by GST play an important role in the INH-induced hepatotoxicity. Since the prevalence of polymorphisms is different in worldwide populations, the risk of ATD hepatotoxicity varies in the populations. Thus, the knowledge of polymorphisms at these loci, prior to medication, may be useful in evaluating risk and controlling ATD hepatotoxicity.